Background
The Pharmacopoeia of the People\’s Republic of China (Chinese Pharmacopoeia, or ChP) is China\’s official collection of standards for drug development, production, sales, utilization, supervision, and control. ChP is updated by the Chinese Pharmacopoeia Commission every five years. The latest version is the ChP 2020, of which the API & excipient standards are listed in BaiPharm Database. In China, all drugs shall comply with the ChP standards to obtain marketing authorization. Therefore, ChemLinked BaiPharm Portal holds this webinar to help drug applicants understand and meet the ChP standards.
Contents
1. China National Drug Standard System
Schedule
| Date | Time (GMT +8) | World Clock | Language |
| 2022-06-15 | 21:00 ~ 22:00 | London: 14:00-15:00 (BST) New York: 9:00-10:00 (EDT) |
English |
Speakers
Grace Wang
ChemLinked Regulatory Analyst
Grace Wang is a regulatory analyst and editor specializing in pharmaceutical regulations and market trends. She provides news and insights to help international pharma companies with market access in China. Her areas of focus include DMF filing, new drug application, pharmacovigilance, and volume-based procurement policy.
Contact Us
If you have any questions about this webinar, please contact us：
Tel: +86 (0)571 8710 3829
Email：contact@chemlinked.com